

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA SHINEWAY PHARMACEUTICAL GROUP LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 02877)**

### **ANNOUNCEMENT OF TURNOVER INFORMATION FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2011**

The Company is pleased to announce its financial information of turnover, which has not been reviewed by its auditors, for the nine months ended 30 September 2011.

The board of directors (the “Board”) of China Shineway Pharmaceutical Group Limited (the “Company”) is pleased to announce the preliminary financial information of turnover of the Company and its subsidiaries (together, the “Group”) for the nine months ended 30 September 2011 based on its management accounts which have not been reviewed by the auditors.

Total turnover of the Group, which has not been reviewed by the auditors, for the nine months ended 30 September 2011 increased by approximately 3.3% as compared with the same period of 2010 to approximately RMB1,453 million, and in particular:

- Turnover for the nine months ended 30 September 2011 of injection products decreased by approximately 7.3% as compared to the same period of 2010 to approximately RMB836 million;
- Turnover for the nine months ended 30 September 2011 of soft capsule products increased by approximately 18.8% as compared to the same period of 2010 to approximately RMB323 million;
- Turnover for the nine months ended 30 September 2011 of granule products increased by approximately 17.5% as compared to the same period of 2010 to approximately RMB242 million; and
- Products in other forms recorded turnover of approximately RMB52 million for the nine months ended 30 September 2011.

In terms of product mix, injection products, soft capsule products and granule products accounted for approximately 57.5%, 22.2% and 16.7% of total turnover which has not been reviewed by the auditors, for the first nine months of 2011.

**Shareholders and investors are advised to exercise caution in dealing in the shares of the Company.**

By order of the Board  
**China Shineway Pharmaceutical Group Limited**  
**Li Zhenjiang**  
*Chairman*

Hong Kong, 7 November 2011

*As at the date of this announcement, the executive Directors are Mr. Li Zhenjiang, Ms. Wang Zhihua, Ms. Xin Yunxia and Mr. Li Huimin, the non-executive Director is Mr. Randy Hung King Kuen and the independent non-executive Directors are Mr. Ren Dequan, Ms. Cheng Li and Mr. Sun Liutai.*